Clinical Trial Update: Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial investigating metformin glycinate for metabolic control and inflammatory mediators in type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• metformin glycinate (metformin glycinate)

Snippet

Sponsor: Laboratorios Silanes S.A. de C.V. | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED